Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020
Authors Lovedeep S. Dhingra, Arya Aminorroaya, Evangelos K. Oikonomou, Arash Aghajani Nargesi, Francis Perry Wilson, Harlan M. Krumholz, Rohan Khera
In this cross-sectional study based on a representative sample of 9,303 U.S. adults in 2019 and 2020, less than a quarter with established cardiovascular disease reported using wearable devices compared with 29% of the general population.
Acetate controls endothelial-to-mesenchymal transition
Authors Xiaolong Zhu, Yunyun Wang, Ioana Soaita, Heon-Woo Lee, Hosung Bae, Nabil Boutagy, Anna Bostwick, Rong-Mo Zhang, Caitlyn Bowman, Yanying Xu, Sophie Trefely, Yu Chen, Lingfeng Qin, William Sessa, George Tellides, Cholsoon Jang, Nathaniel W. Snyder, Luyang Yu, Zoltan Arany, Michael Simons
This study revealed the metabolic basis underlying vascular disease and insights for reversing once incurable diseases.
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Authors Stephen J. Greene, Eric J. Velazquez, Kevin J. Anstrom, Robert M. Clare, Tracy A. DeWald, Mitchell A. Psotka, Andrew P. Ambrosy, Gerin R. Stevens, John J. Rommel, Tamas Alexy, Fassil Ketema, Dong-Yun Kim, Patrice Desvigne-Nickens, Bertram Pitt, Eric L. Eisenstein, Robert J. Mentz
Researchers from the TRANSFORM-HF trial found no significant difference between two loop diuretic agents — torsemide and furosemide — on symptoms and quality of life in patients with heart failure.